Skip to main content
Premium Trial:

Request an Annual Quote

UMN Pharma to Manufacture, Sell Protein Sciences' Flu Vaccine in Japan

NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.
 
Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.
 
One the test is registered with Japanese regulators, UMN will buy commercial quantities of FluBiok from PSC until a commercial manufacturing facility is available in the country.
 
The license terms include a multimillion-dollar upfront payment and double-digit royalties, PSC said.
 
FluBiok has received "accelerated approval" status from the US Food and Drug Administration and PSC said it expects to file a Biologics License Application with the agency in early 2007.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.